KRSNAA vs LALPATHLAB: Stock Comparison
DR. LAL PATH LABS is the larger company by market capitalisation. KRSNAA DIAGNOSTICS shows a lower P/E, while DR. LAL PATH LABS shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
KRSNAA leads 5; LALPATHLAB leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | KRSNAA | LALPATHLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Healthcare Service Provider | Healthcare Service Provider |
Price
| Metric | KRSNAA | LALPATHLAB |
|---|---|---|
| Live Price | ₹528.75 | ₹1,993 |
| Day Change | 2.07% | -0.79% |
| Volume | 1.97 L | 1.45 L |
| 52-Week High | ₹838 | ₹3,309.2 |
| 52-Week Low | ₹463.1 | ₹1,272.6 |
| Distance from 52W High | -36.9% | -39.77% |
Valuation
| Metric | KRSNAA | LALPATHLAB |
|---|---|---|
| Market Cap | ₹1,720 Cr | ₹33,301 Cr |
| P/E Ratio | 17.54x | 57.01x |
| P/B Ratio | 1.66x | 12.11x |
| EPS | ₹7.58 | ₹11.45 |
| Book Value | ₹302.23 | ₹151.4 |
| Dividend Yield | 0.38% | 0.63% |
Growth
| Metric | KRSNAA | LALPATHLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 3.5% | 16.6% |
| EPS Growth (TTM YoY) | 102.1% | -15.4% |
| Qtr Sales Growth | 15.05% | 9.55% |
| Qtr Profit Growth | 48.55% | 13.72% |
Profitability & Leverage
| Metric | KRSNAA | LALPATHLAB |
|---|---|---|
| ROE | 10.35% | 20.06% |
| ROCE | 8.96% | 24.86% |
| Net Margin | 13.13% | 18.27% |
| Operating Margin | 21.33% | 25.04% |
| Debt to Equity | 0.55x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | KRSNAA | LALPATHLAB |
|---|---|---|
| Promoter Holding | 27.11% | 51.09%▼ 0.26 pp |
| FII Holding | 3.84%▼ 0.44 pp | 18.73%▲ 1.37 pp |
| DII Holding | 14.5%▼ 0.01 pp | 21.58%▼ 0.01 pp |
| Public Holding | 54.54%▲ 0.45 pp | 6.35%▼ 1.12 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KRSNAA DIAGNOSTICS and DR. LAL PATH LABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.

